Osteogenic and ewing sarcomas: Estimation of necrotic fraction during induction chemotherapy with dynamic contrastenhanced MR imaging

Radiology

Volumn 228, Issue 1, 2003, Pages 271-278

  Dyke, Jonathan P ^a   Panicek, David M ^a,b   Healey, John H ^b   Meyers, Paul A ^b   Huvos, Andrew G ^b   Schwartz, Lawrence H ^a,b   Thaler, Howard T ^b   Tofts, Paul S ^c   Gorlick, Richard ^b   Koutcher, Jason A ^b   Ballon, Douglas ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NONE

Author keywords

Bone neoplasms, MR; Chemotherapy; Ewing sarcoma; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GADOLINIUM PENTETATE; METHOTREXATE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; EWING SARCOMA; FEMALE; HISTOGRAM; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TUMOR NECROSIS;

ADOLESCENT; ADULT; CHILD; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; NECROSIS; OSTEOSARCOMA; SARCOMA, EWING'S;

EID: 0037600544     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2281011651     Document Type: Article

References (26)

1. De Baere T, Vanel D, Shapeero L, et al. Osteogenic sarcoma after chemotherapy: evaluation with contrast material-enhanced subtraction MR imaging. Radiology 1992; 18S:S87-S92.
2. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering T12 protocol. J Clin Oncol 1998; 16:2452-2458.
3. Wunder JS, Paulian G, Huvos AG, et al. The pathological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998; 80:1020-1033.
4. Pan G, Raymond AK, Carrasco CH, et al. Osteogenic sarcoma: MR imaging after preoperative chemotherapy. Radiology 1990; 174:S17-S26.
5. Holscher HC, Bloem JL, Nooy MA, et al. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. AJR Am J Roentgenol 1990; 154:763-769.
6. Erlemann R, Sciuk J, Bosse A, et al. Response of osteogenic sarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology 1990; 17S:791-796.
7. Reddick W, Langston J, Meyer W, et al. Discrete signal processing of dynamic contrast-enhanced MR imaging: statistical validation and preliminary clinical application. J Magn Reson Imaging 1994; 4:397-404.
8. van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol 1998; 27:57-71.
9. Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 1999; 10:277-285.
10. Lang P, Honda G, Roberts T, et al. Musculoskeletal neoplasm: perineoplastic edema versus tumor on dynamic postcontrast MR images with spatial mapping of instantaneous enhancement rates. Radiology 1995; 197:831-839.
11. Weis LD. The success of limb-salvage surgery in the adolescent patient with osteogenic sarcoma. Adolesc Med 1999; 10:451-458.
12. Hoffer FA, Nikanorov AY, Reddick WE, et al. Accuracy of MR imaging for detecting epiphyseal extension of osteogenic sarcoma. Pediatr Radiol 2000; 30:289-298.
13. Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteogenic sarcoma. J Clin Oncol 1994; 12:2699-2705.
14. Picci P, Sangiorgi L, Bahamonde L, et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteogenic sarcoma of the extremities. Ann Oncol 1997; 8:899-903.
15. Gherlinzoni F, Picci P, Bacci G, Campanacci D. Limb sparing versus amputation in osteogenic sarcoma. Correlation between local control, surgical margins and tumor necrosis: Istituto Rizzoli experience. Ann Oncol 1992; 3(suppl 2):S23-S27.
16. Buckley DL, Kerslake RW, Blackband SJ, Horseman A. Quantitative analysis of multi-slice gadopentetate dimeglumine enhanced dynamic MR images using an automated simplex minimization procedure. Magn Reson Med 1994; 32:646-651.
17. Henderson E, Rutt BK, Lee TY. Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imaging 1998; 16:1057-1073.
18. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10:223-232.
19. Springfield DS, Schakel ME, Spanier SS. Spontaneous necrosis in osteogenic sarcoma. Clin Orthop 1991; 263:233-237.
20. Hoffman U, Brix G, Knopp MV, et al. Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 1995; 33:506-514.
21. Brix G, Semmler W, Port R, et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991; 15:621-628.
22. Tofts PS. Modeling tracer kinetics in dynamic gadopentetate dimeglumine. J Magn Reson Imaging 1997; 7:91-101.
23. Gumbel EJ. Statistics of extremes. New York, NY: Columbia University Press, 1958.
24. Taylor JS, Reddick WE. Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI. Adv Drug Deliv Rev 2000; 41:91-110.
25. Bhujwalla ZM, Artemov D, Glockner J. Tumor angiogenesis, vascularization, and contrast-enhanced magnetic resonance imaging. Top Magn Reson Imaging 1999; 10:92-103.
26. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999; 10:260-266.